Torrent Pharma's Q1 to mark first full quarter of JB Chemicals integration: Nomura
NiveshIQ
NSE: TORNTPHARM · Pharma
Torrent Pharmaceuticals Ltd.
₹4,878.50▼ ₹19.80 (-0.40%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on TORNTPHARM. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Torrent Pharmaceuticals Ltd.
Torrent Pharmaceuticals Limited is a leading Indian pharmaceutical company that engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations across various therapeutic areas. The company generates significant revenue from its presence in India, the United States, Brazil, Germany, and internationally. Its product portfolio includes anti-diabetic, anti-microbial, cardiovascular, and urology products, among others, offered under brands such as Tedibar, Shelcal, Unienzyme, and Ahaglow. Recent developments indicate robust growth in Q4 FY26, with revenue surging 42% year-over-year, driven by India, Brazil, and the semaglutide launch. The company's strong performance is attributed to its diversified presence across key markets
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹10,728 Cr +11.50% | ₹11,516 Cr +7.30% | ₹13,980 Cr +21.40% |
| EBITDA Margin | 31.39% | 32.31% | 31.94% |
| Net Profit | ₹1,656 Cr +33.00% | ₹1,911 Cr +15.40% | ₹2,227 Cr +16.50% |
| EPS | ₹48.94 | ₹56.45 | ₹63.92 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Torrent Pharma's Q1 to mark first full quarter of JB Chemicals integration: Nomura
Torrent Pharma appoints Shanti Ekambaram as director for 3 years
🔒
+ 3 more stories about Torrent Pharmaceuticals Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹4, 197 Cr, PAT ₹430 Cr, EPS ₹11.51, EBITDA margin 31.9%. Growth context: revenue YoY +41.8%, PAT YoY -13.7%, revenue QoQ +27.1%, PAT QoQ -32.3%. Street verdict: inline, revenue surprise +0.8%, PAT surprise +0.9%.
Management commentary points to product launches, approvals, and therapy-mix improvement and new product launches and ma...
FY26 (last completed FY): revenue ₹13, 980 Cr, PAT ₹2, 227 Cr, EBITDA margin 31.9%, EPS ₹63.92. Year-on-year: revenue Yo...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for TORNTPHARM
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track TORNTPHARM alongside your other holdings
Unlock full TORNTPHARM research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Torrent Pharmaceuticals Ltd.?
NiveshIQ detects active intelligence signals for Torrent Pharmaceuticals Ltd. (TORNTPHARM) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Torrent Pharmaceuticals Ltd.?
Torrent Pharmaceuticals Ltd. operates in the Pharma sector with a market capitalisation of ₹14,840,833.0L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.